title: Gaucher Disease: Clinical, Biological and Therapeutic Aspects.
abstract: We present a brief review of Gaucher disease (GD), the most common lysosomal storage disease. GD is a rare autosomal recessive disorder characterized by the defective function of the catabolic enzyme β-glucocerebrosidase (GBA), leading to an accumulation of its substrate, glucocerebroside. Clinical signs and symptoms include neurological dysfunctions, bone infarcts and malformations, hepatosplenomegaly and hypersplenism leading to anemia, neutropenia and thrombocytopenia. Enzyme replacement therapy with recombinant GBA is the mainstay of treatment for GD, which became the first successfully managed lipid storage disease. Future treatments may include oral enzyme replacement and/or gene therapy interventions.
authors.affiliation: Laboratory of Biochemistry, Farhat Hached Hospital, Sousse, Tunisia.
authors.forename: Azza
authors.initials: A
authors.lastname: Dandana
authors.forename: Souhaira
authors.initials: S
authors.lastname: Ben Khelifa
authors.forename: Hinda
authors.initials: H
authors.lastname: Chahed
authors.forename: Abdelhédi
authors.initials: A
authors.lastname: Miled
authors.forename: Salima
authors.initials: S
authors.lastname: Ferchichi
mesh_terms: D056947:Enzyme Replacement Therapy; D005776:Gaucher Disease / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy*; D015316:Genetic Therapy; D005962:Glucosylceramidase / Q000235:genetics / Q000627:therapeutic use; D006801:Humans; D006971:Hypersplenism / Q000209:etiology; D013163:Splenomegaly / Q000209:etiology
chemical_list: D005962:Glucosylceramidase